Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 1998

View Archived Issues

Spotlight on angiogenesis inhibitors in clinical testing

Gene transfer may be an effective strategy for treatment of AIDS-related Kaposi's sarcoma

Caroverine shown to effective treatment for alcohol withdrawal syndrome

Bactericidal actions of plaunotol demonstrated

Novel antiulcer agent effectively reduces gastric bleeding and lesion formation in rats

Elan to acquire Kodak's NanoSystems division

Sugen initiates two new trials with lead compound

Cell Genesys announces positive phase I/II results using GVAX vaccine for prostate cancer

AxyS Pharmaceuticals reaches milestone in Bristol-Myers Squibb collaboration

Procyon receives U.S. patent for the use of ANAs in the treatment of cancer

Novartis to consolidate cell and gene therapy operations

Nortran completes phase II trial of RSD-921

Genetronics reports continued success with electroporation therapy of cancer

Toa Eiyo discloses new adenosine A1 antagonists

New NOS inhibitors prepared at Ono described in patent literature

TAN-2474 compounds from Gliocladium act as complement inhibitors

Takeda describes preparation and use of inhibitors of steroid C17-20 lyase

Collaborative work by Otsuka and Taiho leads to broad-spectrum, water-soluble cephems

Kyowa Hakko reports success in its search for new analgesics

Sodium channel blocker with antiischemic potential emerges from Glaxo Wellcome R&D

Another mGluR1 receptor ligand reported by Lilly

New from Banyu: M3-selective muscarinic antagonists with excellent activity, improved safety

New target for treating HCV infection: NS3-4A proteinase

Neutralase preclinical data published; clinical trial still on hold

Cephalon presents CEP-701 at German cancer meeting

PAF antagonist evaluated in patients with rheumatoid arthritis; results disappointing

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...